Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
NCT00449540 · View on ClinicalTrials.gov ↗
Study Summary
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the spreading cortical brain activity that causes or contributes to the migraine headache. Two TMS treatments at an intensity of \<1 Tesla for \~500 microseconds, approximately 30 seconds apart, may stop the aura and prevent the subsequent headache.
Conditions Studied
Interventions
- DEVICE Active Transcranial Magnetic Stimulation (TMS) Device
- DEVICE Sham TMS Device
Study Locations (14)
Michigan
- Michigan Head Pain & Neurological Institute — Ann Arbor
- Westside Family Medical Center — Kalamazoo
Missouri
- Clinvest, Inc. — Springfield
- Mercy Health Research — St Louis
California
- San Francisco Headache Clinic — San Francisco
Colorado
- Mile High Research Center — Denver
Illinois
- Diamond Headache Clinic, LTD — Chicago
Nebraska
- Kirchner Headache Clinic — Omaha
New York
- Montefiore Headache Center — The Bronx
Ohio
- The Ohio State University — Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449540
The ClinicalTrials.gov registry entry for NCT00449540 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuralieve, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine With Aura appearing as the primary indexed condition, and to 2 interventions — of which Active Transcranial Magnetic Stimulation (TMS) Device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00449540 reports 14 study locations spanning 12 distinct geographic areas — top geographies include Michigan, Missouri, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00449540 about?
NCT00449540 is a clinical study titled "Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura". Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the spreading cortical brain activity that causes or contributes to the migraine h...
What is the current status of trial NCT00449540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2006-08. Estimated completion is 2008-03.
What conditions does trial NCT00449540 study?
This clinical trial studies the following conditions: Migraine With Aura. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00449540?
The interventions under investigation include: Active Transcranial Magnetic Stimulation (TMS) Device (DEVICE), Sham TMS Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00449540?
This trial is sponsored by Neuralieve, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00449540 being conducted?
This trial has 14 study locations across California, Colorado, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.